Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients: a propensity score analysis.

G. Apolone, S. Deandrea, M. Montanari, O. Corli, M. T. Greco, S. Cavuto

Research output: Contribution to journalArticle

Abstract

Transdermal delivery systems containing fentanyl or buprenorphine, despite the relatively lack of comparative studies, have reached an impressive share of the market in several countries. In the context of a wider observational study, we applied the propensity score to test the comparative effectiveness of the two routes of administration (oral vs. transdermal). We applied the propensity score in a subgroup of patients (starting the World Health Organization third step therapy during the scheduled follow-up of 28 days) using pre-planned primary (pain intensity change) and secondary endpoints, such as increase in doses, need for switching and safety profile. Univariate and multivariate analyses were carried out. Three-hundred sixty-six eligible cases were analysed. We found a difference among the two groups in terms of variables potentially associated with therapy choice and outcomes. After adjusting for propensity score, results were in favour of transdermal delivery systems for the primary endpoint (odds ratio 1.68; p = 0.04). A similar trend was also present for the other secondary endpoints. Only in the case of nausea and vomiting, patients receiving transdermal delivery systems reported a higher frequency of events. The application of the propensity score has helped understand better the actual effectiveness of transdermal delivery systems that are at least equivalent to the oral opioids, and even more effective for pain intensity reduction.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalEuropean Journal of Pain (United Kingdom)
Volume16
Issue number2
Publication statusPublished - Feb 2012

Fingerprint

Propensity Score
Opioid Analgesics
Analgesics
Neoplasms
Pain
Buprenorphine
Fentanyl
Nausea
Vomiting
Observational Studies
Oral Administration
Multivariate Analysis
Odds Ratio
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients : a propensity score analysis. / Apolone, G.; Deandrea, S.; Montanari, M.; Corli, O.; Greco, M. T.; Cavuto, S.

In: European Journal of Pain (United Kingdom), Vol. 16, No. 2, 02.2012, p. 229-238.

Research output: Contribution to journalArticle

@article{2f4209fd0fe24fd6ae44fe512a48cc29,
title = "Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients: a propensity score analysis.",
abstract = "Transdermal delivery systems containing fentanyl or buprenorphine, despite the relatively lack of comparative studies, have reached an impressive share of the market in several countries. In the context of a wider observational study, we applied the propensity score to test the comparative effectiveness of the two routes of administration (oral vs. transdermal). We applied the propensity score in a subgroup of patients (starting the World Health Organization third step therapy during the scheduled follow-up of 28 days) using pre-planned primary (pain intensity change) and secondary endpoints, such as increase in doses, need for switching and safety profile. Univariate and multivariate analyses were carried out. Three-hundred sixty-six eligible cases were analysed. We found a difference among the two groups in terms of variables potentially associated with therapy choice and outcomes. After adjusting for propensity score, results were in favour of transdermal delivery systems for the primary endpoint (odds ratio 1.68; p = 0.04). A similar trend was also present for the other secondary endpoints. Only in the case of nausea and vomiting, patients receiving transdermal delivery systems reported a higher frequency of events. The application of the propensity score has helped understand better the actual effectiveness of transdermal delivery systems that are at least equivalent to the oral opioids, and even more effective for pain intensity reduction.",
author = "G. Apolone and S. Deandrea and M. Montanari and O. Corli and Greco, {M. T.} and S. Cavuto",
year = "2012",
month = "2",
language = "English",
volume = "16",
pages = "229--238",
journal = "EUR.J.PAIN",
issn = "1090-3801",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients

T2 - a propensity score analysis.

AU - Apolone, G.

AU - Deandrea, S.

AU - Montanari, M.

AU - Corli, O.

AU - Greco, M. T.

AU - Cavuto, S.

PY - 2012/2

Y1 - 2012/2

N2 - Transdermal delivery systems containing fentanyl or buprenorphine, despite the relatively lack of comparative studies, have reached an impressive share of the market in several countries. In the context of a wider observational study, we applied the propensity score to test the comparative effectiveness of the two routes of administration (oral vs. transdermal). We applied the propensity score in a subgroup of patients (starting the World Health Organization third step therapy during the scheduled follow-up of 28 days) using pre-planned primary (pain intensity change) and secondary endpoints, such as increase in doses, need for switching and safety profile. Univariate and multivariate analyses were carried out. Three-hundred sixty-six eligible cases were analysed. We found a difference among the two groups in terms of variables potentially associated with therapy choice and outcomes. After adjusting for propensity score, results were in favour of transdermal delivery systems for the primary endpoint (odds ratio 1.68; p = 0.04). A similar trend was also present for the other secondary endpoints. Only in the case of nausea and vomiting, patients receiving transdermal delivery systems reported a higher frequency of events. The application of the propensity score has helped understand better the actual effectiveness of transdermal delivery systems that are at least equivalent to the oral opioids, and even more effective for pain intensity reduction.

AB - Transdermal delivery systems containing fentanyl or buprenorphine, despite the relatively lack of comparative studies, have reached an impressive share of the market in several countries. In the context of a wider observational study, we applied the propensity score to test the comparative effectiveness of the two routes of administration (oral vs. transdermal). We applied the propensity score in a subgroup of patients (starting the World Health Organization third step therapy during the scheduled follow-up of 28 days) using pre-planned primary (pain intensity change) and secondary endpoints, such as increase in doses, need for switching and safety profile. Univariate and multivariate analyses were carried out. Three-hundred sixty-six eligible cases were analysed. We found a difference among the two groups in terms of variables potentially associated with therapy choice and outcomes. After adjusting for propensity score, results were in favour of transdermal delivery systems for the primary endpoint (odds ratio 1.68; p = 0.04). A similar trend was also present for the other secondary endpoints. Only in the case of nausea and vomiting, patients receiving transdermal delivery systems reported a higher frequency of events. The application of the propensity score has helped understand better the actual effectiveness of transdermal delivery systems that are at least equivalent to the oral opioids, and even more effective for pain intensity reduction.

UR - http://www.scopus.com/inward/record.url?scp=84871694827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871694827&partnerID=8YFLogxK

M3 - Article

C2 - 22323375

AN - SCOPUS:84871694827

VL - 16

SP - 229

EP - 238

JO - EUR.J.PAIN

JF - EUR.J.PAIN

SN - 1090-3801

IS - 2

ER -